CoChat

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors

Open access

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Abstract

Cancer cells bearing distinct KRAS mutations exhibit variable sensitivity to SHP2 inhibitors (SHP2i). Here we show that cells harboring KRAS Q61H are uniquely resistant to SHP2i, and investigate the underlying mechanisms using biophysics, molecular dynamics, and cell-based approaches. Q61H mutation impairs intrinsic and GAP-mediated GTP hydrolysis, and impedes activation by SOS1, but does not alter tyrosyl phosphorylation. Wild-type and Q61H-mutant KRAS are both phosphorylated by Src on Tyr32 and Tyr64 and dephosphorylated by SHP2, however, SHP2i does not reduce ERK phosphorylation in KRAS Q61H cells. Phosphorylation of wild-type and Gly12-mutant KRAS, which are associated with sensitivity to SHP2i, confers resistance to regulation by GAP and GEF activities and impairs binding to RAF, whereas the near-complete GAP/GEF-resistance of KRAS Q61H remains unaltered, and high-affinity RAF interaction is retained. SHP2 can stimulate KRAS signaling by modulating GEF/GAP activities and dephosphorylating KRAS, processes that fail to regulate signaling of the Q61H mutant.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-26526-y

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 KRAS Q61H mutant cells exhibit insensitivity to pharmacologic inhibition of SHP2 (SHP2i). a Schematic cartoon illustrating proposed catalytic and scaffolding roles of SHP2 in modulating KRAS signaling. SHP2 scaffolds the GRB2:SOS complex to activated receptor tyrosine kinases to promote RAS activation, whereas its phosphatase activity inhibits Sprouty’s negative regulation of SOS (left) and dephosphorylates a pTyr docking site for p120RASGAP on GAB1, thereby reducing inactivation of KRAS (right). Top: SHP2 also dephosphorylates KRAS, release it from the “dark state” and restoring KRAS signaling. b PDAC cell lines (left) or PDX cells (right) were plated in 96-well plates in triplicate, treated with increasing concentrations of the SHP2 inhibitor 11a-1 for 48 h, then cell viability was determined using alamarBlue. GI50 values were determined using GraphPad Prism 6.0. Data represent mean ± SEM of three independent experiments. c CFPAC1 or Hs766T cells were seeded at 1000 cells/well in 96-well spheroid microplates. Spheroids were cultured for 48 h and then exposed to vehicle (DMSO) or 50 μM 11a-1. Following 48 h incubation with 11a-1, a 3D cell viability assay was performed. Left: representative images obtained using a VWR Vista Vision inverted microscope. Scale bar, 100 μm. Right: data represent mean ± SEM. RLU (relative light units) of three independent experiments. To compare the 11a-1-treated and control group, p-value was generated using two-tailed Student’s t-test. d PDAC or lung cancer cell lines were treated with the increasing concentrations of the SHP2 inhibitor SHP099 (0, 5, 10, 20 µM) for 2 h. Equal amounts of lysates were resolved on SDS-PAGE and immunoblotted with the indicated antibodies. e CRISPR/Cas9-mediated non-target (Ctrl) or SHP2−/− CFPAC1, HPAF-II, and Hs766T cells were serum-starved and treated with (+) or without (−) EGF (10 ng/ml). Equal amounts of lysates were immunoprecipitated and immunoblotted with the indicated antibodies. f HEK293 cells were transfected with mock, HA-KRAS WT, or HA-KRAS Q61H plasmids, as indicated. Cells were cultured for 48 h and then exposed to increasing concentrations of SHP099 (0, 2, 5, 10, 20 µM) for 2 h. Equal amounts of lysates were resolved on SDS-PAGE and immunoblotted with the indicated antibodies. Numbers indicate pERK levels normalized to vinculin based on densitometry. g HEK293 cells stably overexpressing GFP-KRAS WT, GFP-KRAS Q61H, or GFP with 11a-1 and cell viability was assessed at 48 h using alamarBlue. Data represent mean ± SEM of three independent experiments. The GFP and GFP-KRAS WT groups were independently compared with GFP-KRAS Q61H group using two-tailed Student’s t-test. The respective p-values are indicated on the figure. d–f The blots are representative of three independent experiments.
Fig. 1 KRAS Q61H mutant cells exhibit insensitivity to pharmacologic inhibition of SHP2 (SHP2i). a Schematic cartoon illustrating proposed catalytic and scaffolding roles of SHP2 in modulating KRAS signaling. SHP2 scaffolds the GRB2:SOS complex to activated receptor tyrosine kinases to promote RAS activation, whereas its phosphatase activity inhibits Sprouty’s negative regulation of SOS (left) and dephosphorylates a pTyr docking site for p120RASGAP on GAB1, thereby reducing inactivation of KRAS (right). Top: SHP2 also dephosphorylates KRAS, release it from the “dark state” and restoring KRAS signaling. b PDAC cell lines (left) or PDX cells (right) were plated in 96-well plates in triplicate, treated with increasing concentrations of the SHP2 inhibitor 11a-1 for 48 h, then cell viability was determined using alamarBlue. GI50 values were determined using GraphPad Prism 6.0. Data represent mean ± SEM of three independent experiments. c CFPAC1 or Hs766T cells were seeded at 1000 cells/well in 96-well spheroid microplates. Spheroids were cultured for 48 h and then exposed to vehicle (DMSO) or 50 μM 11a-1. Following 48 h incubation with 11a-1, a 3D cell viability assay was performed. Left: representative images obtained using a VWR Vista Vision inverted microscope. Scale bar, 100 μm. Right: data represent mean ± SEM. RLU (relative light units) of three independent experiments. To compare the 11a-1-treated and control group, p-value was generated using two-tailed Student’s t-test. d PDAC or lung cancer cell lines were treated with the increasing concentrations of the SHP2 inhibitor SHP099 (0, 5, 10, 20 µM) for 2 h. Equal amounts of lysates were resolved on SDS-PAGE and immunoblotted with the indicated antibodies. e CRISPR/Cas9-mediated non-target (Ctrl) or SHP2−/− CFPAC1, HPAF-II, and Hs766T cells were serum-starved and treated with (+) or without (−) EGF (10 ng/ml). Equal amounts of lysates were immunoprecipitated and immunoblotted with the indicated antibodies. f HEK293 cells were transfected with mock, HA-KRAS WT, or HA-KRAS Q61H plasmids, as indicated. Cells were cultured for 48 h and then exposed to increasing concentrations of SHP099 (0, 2, 5, 10, 20 µM) for 2 h. Equal amounts of lysates were resolved on SDS-PAGE and immunoblotted with the indicated antibodies. Numbers indicate pERK levels normalized to vinculin based on densitometry. g HEK293 cells stably overexpressing GFP-KRAS WT, GFP-KRAS Q61H, or GFP with 11a-1 and cell viability was assessed at 48 h using alamarBlue. Data represent mean ± SEM of three independent experiments. The GFP and GFP-KRAS WT groups were independently compared with GFP-KRAS Q61H group using two-tailed Student’s t-test. The respective p-values are indicated on the figure. d–f The blots are representative of three independent experiments.CC BY · PubMed Central
Fig. 2 KRAS Q61H is insensitive to GEF and GAP activities. a Intrinsic nucleotide-exchange curves of wild-type (WT) and mutant KRAS obtained from real-time NMR experiments. A tenfold molar excess of GTPγS was added to GDP-loaded KRAS at t = 0 and the GDP-bound fraction remaining was monitored over time by NMR. The data were fit to one-phase exponential decay functions. The nucleotide-exchange curves do not go to zero, because the nucleotide exchange equilibrates at a certain ratio, which is a function of the relative affinity of GDP:GTPγS. b Histogram of intrinsic exchange rates of each mutant determined in a, presented as fold changes for the mutants relative to wild-type KRAS. The error bars indicate the SD of the fold changes. c GEF-assisted nucleotide-exchange curves in the presence of SOScat (1 : 600 molar ratio SOS : KRAS), measured using real-time NMR. Data were fit as in a. d Histogram representing the mean intrinsic and SOScat (1 : 600) assisted exchange rates for wild-type KRAS and mutants obtained from three independent fitting curves for each mutation. Three pair of peak intensities for each group were used to generate the fitting curves. The error bars represent SEM of the three exchange rates. e A snapshot ribbon diagram of SOS1 (red) in complex with WT-KRAS (blue) (top panel). Time evolution of hydrogen bonds formed between the Thr935 of SOS and the sidechain of KRAS Q61 (bottom panel). f A snapshot ribbon diagram of SOS1 (red) in complex with KRAS Q61H (orange) (top panel). Time evolution of hydrogen bonds formed between the Thr935 of SOS and the sidechain of KRAS His61. g Intrinsic and GAP-assisted GTP hydrolysis curves for the wild type and Q61H mutant. The GAP domain of RASA1 was added at a ratio of 1 : 3000 to KRAS-GTP (a, c, e). h A ribbon diagram of RasGAP (blue) and KRAS Q61H (orange) catalytic site. Dots represent the fraction of GDP-loaded KRAS based on the intensities of GDP- and GTP-specific peaks (IGDP/IGDP + IGTPγS). a, b, g Error bars represent SEM of the three independent pairs of peak intensities used for the calculation.
Fig. 2 KRAS Q61H is insensitive to GEF and GAP activities. a Intrinsic nucleotide-exchange curves of wild-type (WT) and mutant KRAS obtained from real-time NMR experiments. A tenfold molar excess of GTPγS was added to GDP-loaded KRAS at t = 0 and the GDP-bound fraction remaining was monitored over time by NMR. The data were fit to one-phase exponential decay functions. The nucleotide-exchange curves do not go to zero, because the nucleotide exchange equilibrates at a certain ratio, which is a function of the relative affinity of GDP:GTPγS. b Histogram of intrinsic exchange rates of each mutant determined in a, presented as fold changes for the mutants relative to wild-type KRAS. The error bars indicate the SD of the fold changes. c GEF-assisted nucleotide-exchange curves in the presence of SOScat (1 : 600 molar ratio SOS : KRAS), measured using real-time NMR. Data were fit as in a. d Histogram representing the mean intrinsic and SOScat (1 : 600) assisted exchange rates for wild-type KRAS and mutants obtained from three independent fitting curves for each mutation. Three pair of peak intensities for each group were used to generate the fitting curves. The error bars represent SEM of the three exchange rates. e A snapshot ribbon diagram of SOS1 (red) in complex with WT-KRAS (blue) (top panel). Time evolution of hydrogen bonds formed between the Thr935 of SOS and the sidechain of KRAS Q61 (bottom panel). f A snapshot ribbon diagram of SOS1 (red) in complex with KRAS Q61H (orange) (top panel). Time evolution of hydrogen bonds formed between the Thr935 of SOS and the sidechain of KRAS His61. g Intrinsic and GAP-assisted GTP hydrolysis curves for the wild type and Q61H mutant. The GAP domain of RASA1 was added at a ratio of 1 : 3000 to KRAS-GTP (a, c, e). h A ribbon diagram of RasGAP (blue) and KRAS Q61H (orange) catalytic site. Dots represent the fraction of GDP-loaded KRAS based on the intensities of GDP- and GTP-specific peaks (IGDP/IGDP + IGTPγS). a, b, g Error bars represent SEM of the three independent pairs of peak intensities used for the calculation.CC BY · PubMed Central
Fig. 3 KRAS Q61H is phosphorylated by Src and dephosphorylated by SHP2. a HEK293 cells were transfected with HA-tagged KRAS WT, G12D, G12V, or Q61H and either kinase-dead (KD) or active (WT) Src. KRAS was immunoprecipitated with anti-HA antibody, resolved on SDS-PAGE, and immunoblotted with anti-pTyr. Equal amounts of lysates were resolved on SDS-PAGE and immunoblotted with an antibody recognizing phosphorylated KRAS Y64, as well as the antibodies indicated to confirm expression and loading. b KRAS Q61H loaded with GDP or a non-hydrolysable GTP-analog (GMPPNP) was incubated with Src (1 : 250 Src to KRAS ratio) and ATP, and the reaction products were analyzed with mass spectrometry. The predicted mass of 15N-KRAS Q61H (residues 1–173 C118S) is 20084.36. Peaks corresponding to unmodified KRAS Q61H, as well as KRAS Q61H phosphorylated at one (+80 Da) and two sites (+160 Da) are labeled accordingly. c KRAS4B Q61H sequence indicating tryptic peptides in which phosphotyrosine was detected (orange letters with blue arrows indicating trypsin cleavage sites). d, e LC-MS analyses of phosphorylated tyrosine residues in KRAS Q61H. Two phosphorylated tyrosine residues from the KRAS Q61H protein sequence were identified from in vitro kinase reaction samples that were reduced/alkylated, trypsin-digested, and analyzed by LC-MS. MS/MS spectra matched KRAS tryptic peptides containing phosphorylated d Y32 and e Y64. f HEK293 cells were transfected with HA-KRAS WT, Q61H, Y32F/Q61H, or Q61H/Y64F mutants, with or without co-transfection of Src. HA-KRAS was immunoprecipitated with anti-HA and probed with anti-pTyr antibody. The whole-cell extracts were resolved on SDS-PAGE and immunoblotted with an antibody recognizing KRAS pTyr64, as well as those indicated, to confirm expression and loading. g HEK293 cells were transfected with HA-KRAS WT or Q61H increasing amounts of SHP2, with or without co-transfection of Src. HA-KRAS was immunoprecipitated with HA antibody and blotted with pTyr antibody. The whole-cell extracts (WCEs) were blotted with the antibodies indicated to confirm expression and loading. All immunoblot data are representative of at least three independent experiments. h Src-phosphorylated KRAS Q61H was incubated with SHP2 for 2 h and the total mass was analyzed using LC/MS as explained in “Methods.” The predicted mass of unmodified 15N-KRAS Q61H (residues 1–173 C118S) is 20084.36. i CRISPR/Cas9-mediated non-target (SHP2+/+) or SHP2−/− Hs766T cells were serum-starved for 20 h and and treated with (200 ng/ml) (+) or without (−) EGF for 1.5 min. One milligram of lysates was immunoprecipitated and immunoblotted with the indicated antibodies. a, f, g, i The blots are representative of three independent experiments.
Fig. 3 KRAS Q61H is phosphorylated by Src and dephosphorylated by SHP2. a HEK293 cells were transfected with HA-tagged KRAS WT, G12D, G12V, or Q61H and either kinase-dead (KD) or active (WT) Src. KRAS was immunoprecipitated with anti-HA antibody, resolved on SDS-PAGE, and immunoblotted with anti-pTyr. Equal amounts of lysates were resolved on SDS-PAGE and immunoblotted with an antibody recognizing phosphorylated KRAS Y64, as well as the antibodies indicated to confirm expression and loading. b KRAS Q61H loaded with GDP or a non-hydrolysable GTP-analog (GMPPNP) was incubated with Src (1 : 250 Src to KRAS ratio) and ATP, and the reaction products were analyzed with mass spectrometry. The predicted mass of 15N-KRAS Q61H (residues 1–173 C118S) is 20084.36. Peaks corresponding to unmodified KRAS Q61H, as well as KRAS Q61H phosphorylated at one (+80 Da) and two sites (+160 Da) are labeled accordingly. c KRAS4B Q61H sequence indicating tryptic peptides in which phosphotyrosine was detected (orange letters with blue arrows indicating trypsin cleavage sites). d, e LC-MS analyses of phosphorylated tyrosine residues in KRAS Q61H. Two phosphorylated tyrosine residues from the KRAS Q61H protein sequence were identified from in vitro kinase reaction samples that were reduced/alkylated, trypsin-digested, and analyzed by LC-MS. MS/MS spectra matched KRAS tryptic peptides containing phosphorylated d Y32 and e Y64. f HEK293 cells were transfected with HA-KRAS WT, Q61H, Y32F/Q61H, or Q61H/Y64F mutants, with or without co-transfection of Src. HA-KRAS was immunoprecipitated with anti-HA and probed with anti-pTyr antibody. The whole-cell extracts were resolved on SDS-PAGE and immunoblotted with an antibody recognizing KRAS pTyr64, as well as those indicated, to confirm expression and loading. g HEK293 cells were transfected with HA-KRAS WT or Q61H increasing amounts of SHP2, with or without co-transfection of Src. HA-KRAS was immunoprecipitated with HA antibody and blotted with pTyr antibody. The whole-cell extracts (WCEs) were blotted with the antibodies indicated to confirm expression and loading. All immunoblot data are representative of at least three independent experiments. h Src-phosphorylated KRAS Q61H was incubated with SHP2 for 2 h and the total mass was analyzed using LC/MS as explained in “Methods.” The predicted mass of unmodified 15N-KRAS Q61H (residues 1–173 C118S) is 20084.36. i CRISPR/Cas9-mediated non-target (SHP2+/+) or SHP2−/− Hs766T cells were serum-starved for 20 h and and treated with (200 ng/ml) (+) or without (−) EGF for 1.5 min. One milligram of lysates was immunoprecipitated and immunoblotted with the indicated antibodies. a, f, g, i The blots are representative of three independent experiments.CC BY · PubMed Central
Fig. 4 Phosphorylation enhances the intrinsic exchange of KRAS Q61H. a Intrinsic and SOScat (1 : 600 molar ratio) assisted KRAS nucleotide-exchange curves of unmodified and phosphorylated KRAS Q61H. b Nucleotide-exchange rates derived by fitting the curves in a. c Intrinsic and RASA1 GAP (1 : 3000 molar ratio)-catalyzed KRAS-GTP hydrolysis curves of unmodified and phosphorylated KRAS Q61H. d GTP hydrolysis rates derived by fitting the curves in c. e Overlaid 1H-15N HSQC NMR spectra of wild-type KRAS (WT) and the Q61H mutant, as well as their phosphorylated forms (pWT and pQ61H). Peaks for selected Switch I and II residues are expanded on the right. a–e Phosphorylated KRAS samples were generated by incubating 15N-KRAS with Src (1 : 250 ratio) and ATP followed by passage through a Superdex 75 10/300 column (GE Healthcare). Nucleotide exchange and hydrolysis rates were measured using real-time NMR, starting with fully GDP- and GTP-loaded KRAS Q61H samples, respectively. a, c Dots represent the fraction of KRAS that is GDP loaded (IGDP/IGDP + IGTPγS) based on the intensities of peaks from three residues. The line was obtained by fitting a one-phase exponential decay curve. Error bars indicate the SEM of the rate calculated from three residues peak intensities. b, d Histograms indicate the mean exchange or hydrolysis rates calculated from intensities of three residues. The error bars represent SEM of the respective rates.
Fig. 4 Phosphorylation enhances the intrinsic exchange of KRAS Q61H. a Intrinsic and SOScat (1 : 600 molar ratio) assisted KRAS nucleotide-exchange curves of unmodified and phosphorylated KRAS Q61H. b Nucleotide-exchange rates derived by fitting the curves in a. c Intrinsic and RASA1 GAP (1 : 3000 molar ratio)-catalyzed KRAS-GTP hydrolysis curves of unmodified and phosphorylated KRAS Q61H. d GTP hydrolysis rates derived by fitting the curves in c. e Overlaid 1H-15N HSQC NMR spectra of wild-type KRAS (WT) and the Q61H mutant, as well as their phosphorylated forms (pWT and pQ61H). Peaks for selected Switch I and II residues are expanded on the right. a–e Phosphorylated KRAS samples were generated by incubating 15N-KRAS with Src (1 : 250 ratio) and ATP followed by passage through a Superdex 75 10/300 column (GE Healthcare). Nucleotide exchange and hydrolysis rates were measured using real-time NMR, starting with fully GDP- and GTP-loaded KRAS Q61H samples, respectively. a, c Dots represent the fraction of KRAS that is GDP loaded (IGDP/IGDP + IGTPγS) based on the intensities of peaks from three residues. The line was obtained by fitting a one-phase exponential decay curve. Error bars indicate the SEM of the rate calculated from three residues peak intensities. b, d Histograms indicate the mean exchange or hydrolysis rates calculated from intensities of three residues. The error bars represent SEM of the respective rates.CC BY · PubMed Central
Fig. 5 KRAS Q61H is resistant to regulation of RAF-RBD binding by tyrosyl phosphorylation. a Histogram representing the dissociation constant (Kd) for the binding of unmodified, singly or doubly phosphorylated wild-type or Q61H mutant KRAS to BRAF-RBD. The phosphorylated forms were separated using ion-exchange chromatography and binding to immobilized RBD was measured using BLI. The error bars indicate SEM of three independent measurements. b HEK293 cells were transfected with G12V or Q61H HA-KRAS together with increasing amounts of Src. Cells were lysed and activated HA-KRAS was pulled down with RAF1:RBD-conjugated beads and immunoblotted with anti-HA. The whole-cell extract (WCE) was resolved by SDS-PAGE and probed with the indicated antibodies to confirm expression and loading. Numbers indicate normalized ratios of activated KRAS to total KRAS based on densitometry. The immunoblottings are representative of at least three independent experiments. c A line graph that shows root mean square fluctuation (RMSF) of WT-KRAS (top, modified-red, unmodified-blue) and KRAS Q61H (bottom, modified-brown, unmodified-green). The X-axis shows the residue id for the proteins and the Y-axis is for fluctuation distance in Å. d Model summarizing the impact of Q61H mutation and tyrosyl phosphorylation on the KRAS GTPase cycle and RBD binding. Line thicknesses represent relative rates of each step in the GTPase cycle. The upper panels (from left to right) show the impact of phosphorylation on the GTPase cycle of KRAS WT: reduced sensitivity to the activity of GAPs and GEFs, and impaired binding to RAF. The left panels (from top to bottom) show the impact of the Q61H mutation on the GTPase cycle of KRAS: reduced sensitivity to the activity of GAPs and GEFs with little impact on RAF. The lower panels (from left to right) represent how phosphorylation of the KRAS Q61H mutant has little additional impact on its GTPase cycle.
Fig. 5 KRAS Q61H is resistant to regulation of RAF-RBD binding by tyrosyl phosphorylation. a Histogram representing the dissociation constant (Kd) for the binding of unmodified, singly or doubly phosphorylated wild-type or Q61H mutant KRAS to BRAF-RBD. The phosphorylated forms were separated using ion-exchange chromatography and binding to immobilized RBD was measured using BLI. The error bars indicate SEM of three independent measurements. b HEK293 cells were transfected with G12V or Q61H HA-KRAS together with increasing amounts of Src. Cells were lysed and activated HA-KRAS was pulled down with RAF1:RBD-conjugated beads and immunoblotted with anti-HA. The whole-cell extract (WCE) was resolved by SDS-PAGE and probed with the indicated antibodies to confirm expression and loading. Numbers indicate normalized ratios of activated KRAS to total KRAS based on densitometry. The immunoblottings are representative of at least three independent experiments. c A line graph that shows root mean square fluctuation (RMSF) of WT-KRAS (top, modified-red, unmodified-blue) and KRAS Q61H (bottom, modified-brown, unmodified-green). The X-axis shows the residue id for the proteins and the Y-axis is for fluctuation distance in Å. d Model summarizing the impact of Q61H mutation and tyrosyl phosphorylation on the KRAS GTPase cycle and RBD binding. Line thicknesses represent relative rates of each step in the GTPase cycle. The upper panels (from left to right) show the impact of phosphorylation on the GTPase cycle of KRAS WT: reduced sensitivity to the activity of GAPs and GEFs, and impaired binding to RAF. The left panels (from top to bottom) show the impact of the Q61H mutation on the GTPase cycle of KRAS: reduced sensitivity to the activity of GAPs and GEFs with little impact on RAF. The lower panels (from left to right) represent how phosphorylation of the KRAS Q61H mutant has little additional impact on its GTPase cycle.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 84 references

Research works printed but not linked: 2

  1. Lu, H. et al. SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors. Mol. Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-18-0852 (2019). · DOI · Paper page
  2. Nichols, R. J. et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat. Cell Biol. https://doi.org/10.1038/s41556-018-0169-1 (2018). · DOI · Paper page

Cited by

See all 50

Metadata

Authors
Gebregiworgis, T., Kano, Y., St-Germain, J., Radulovich, N., Udaskin, M. L., Mentes, A., Huang, R., Poon, B. P. K., He, W., Valencia-Sama, I., Robinson, C. M., Huestis, M., Miao, J., Yeh, J. J., Zhang, Z.-Y., Irwin, M. S., Lee, J. E., Tsao, M.-S., Raught, B., Marshall, C. B., Ohh, M., & Ikura, M.
Affiliations
  • University Health Network (CA)
  • Tokyo Medical and Dental University (JP)
  • University of Toronto (CA)
  • Purdue University West Lafayette (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
  • Marshall, Christopher B.
  • Ohh, Michael
  • Ikura, Mitsuhiko
Venue
Nature Communications
Published
2021-11-01
Volume
12
Issue
1
Pages
6274-6274
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3210161753
Cited by
49
References
83
Citations by year
2026: 9 · 2025: 9 · 2024: 13 · 2023: 8 · 2022: 10
FWCI
2.43
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health
  • Canadian Institutes of Health Research (133694_1, FDN‐1542284, PJT-166005,)
  • Canadian Cancer Society Research Institute (703209)
  • Japan Society for the Promotion of Science (19K23909, 166005)
  • National Cancer Institute (R01CA207288, R01CA069202)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
SHP2 inhibitors, drug resistance, GTP hydrolysis, SOS1, GTPase-activating protein, guanine nucleotide exchange factor, ERK1/2 phosphorylation, Src kinase, KRAS signaling
MeSH terms
Enzyme Inhibitors, Guanosine Triphosphate, Humans, Lung Neoplasms, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), src-Family Kinases, Mutation, Missense, Cell Line, Tumor, raf Kinases, Protein Tyrosine Phosphatase, Non-Receptor Type 11

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. https://app.cochat.ai/papers/10.1038/s41467-021-26526-y
The paper
Gebregiworgis, T., Kano, Y., St-Germain, J., Radulovich, N., Udaskin, M. L., Mentes, A., Huang, R., Poon, B. P. K., He, W., Valencia-Sama, I., Robinson, C. M., Huestis, M., Miao, J., Yeh, J. J., Zhang, Z.-Y., Irwin, M. S., Lee, J. E., Tsao, M.-S., Raught, B., . . . Ikura, M. (2021). The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Nature Communications. https://doi.org/10.1038/s41467-021-26526-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.